Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 5/20 | 0.32 |
| ▸ | ABL1 | P00519 | 3/20 | 0.32 |
| ▸ | EGFR | P00533 | 3/20 | 0.32 |
| ▸ | ABL2 | P42684 | 3/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.31 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16611418 | 0.82 | RORC (0.35) | RORCSRCABL1EGFRABL2 | |
| SCHEMBL16611574 | 0.82 | RORC (0.36) | RORCSRCABL1EGFRABL2 | |
| SCHEMBL16611165 | 0.82 | ABL1 (0.41) | SRCABL1EGFRABL2RET | |
| SCHEMBL16611226 | 0.80 | SRC (0.44) | SRCABL1EGFRABL2RIPK2 | |
| SCHEMBL16611724 | 0.79 | RET (0.40) | RET | |
| SCHEMBL16611003 | 0.79 | PIK3CG (0.36) | SRCABL1EGFRABL2RET | |
| SCHEMBL16611241 | 0.79 | SRC (0.43) | SRCABL1EGFRABL2RET | |
| SCHEMBL16610877 | 0.78 | SRC (0.46) | SRCABL1EGFRABL2RET | |
| SCHEMBL16610728 | 0.78 | ROCK2 (0.35) | SRCABL1EGFRABL2 | |
| SCHEMBL16611632 | 0.78 | LRRK2 (0.38) | SRCABL1EGFRABL2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | RORC 538/4885SRC 1557/4885ABL1 1046/4885 |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | RORC 538/4885SRC 1557/4885ABL1 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.